{'fraction_non_alphanumeric': 0.028346456692913385, 'fraction_numerical': 0.0, 'mean_word_length': 5.913043478260869, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Plasma platelet aggregating factor and platelet aggregation studies in pre‐eclampsia

Objective. A plasma platelet aggregating factor (PAF) has been implicated in the pathogenesis of platelet activation in thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Similar mechanism may be operative in pre‐eclampsia. Methods. Coagulation profile and detailed in vitro platelet aggregation with various agonists were studied. PAF was demonstrated by spontaneous aggregation of normal platelets with test plasma. Non‐parametric Wilcoxon's rank sum test and Krauskal Wally's one way analysis of variance were applied.